Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
2cureX ABFRA:2QE -14.23%28 EV-to-EBIT is -1.95 as of Aug. 26, 2026. GuruFocus rates FRA:2QE with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 380 Biotechnology companies, 2cureX AB ranks worse than 263157.63% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
2cureX AB's Enterprise Value for the quarter that ended in Jun. 2025 was €6.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 2cureX AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB EV-to-EBIT Related Terms
2cureX AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for 2cureX AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QE vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, 2cureX AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where 2cureX AB's EV-to-EBIT falls into.
2cureX AB's current Enterprise Value is €1.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 2cureX AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB (FRA:2QE) has a EV-to-EBIT of -1.95 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 2cureX AB and its competitors. According to the industry distribution chart, 2cureX AB ranks #999999 out of 380 companies in the Biotechnology industry.
Is 2cureX AB's EV-to-EBIT too high?
2cureX AB's current EV-to-EBIT is -1.95. Based on the distribution chart, 2cureX AB ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 2cureX AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 2cureX AB ranks #999999 out of 380 companies for EV-to-EBIT. This places 2cureX AB in the lower half of its industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.86, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 2cureX AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 2cureX AB's current EV-to-EBIT is -1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current EV-to-EBIT of -1.95. The current EV-to-EBIT is -1.95. 2cureX AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current EV-to-EBIT is -1.95 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
28GF Score
Get the complete analysis for FRA:2QE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QE has been successfully added to your 
